The Future of Synthetic Cannabinoids

Marijuana has been proven clinically to offer medical benefits such as muscle spasticity and reducing neuropathic pain. Efforts to provide these benefits have allowed US Food and Drug Administration have led to the development and approval of approvable of Marinol, which has the active ingredient dronabinol, also known as Δ9-THC. This drug can be prescribed legally to reduce vomiting, nausea, and increase appetite. Of course, as with all medicines there are possible side effects which include not only the high feeling, but paranoia, seizures, fast heart rate, unusual thoughts, unusual behavior, drowsiness, anxiety, dizziness, mood changes, and fainting. There have been attempts to decrease the THC by mixing with other CBS such as cannabidiol or terpenoids. The idea is that blending these will provide greater benefits such as any male movie star being surrounded by gorgeous blondes.

In 2011, the American Association of Poison Centers had 6,959 call concerning exposure to synthetic CB’s. The National Poison Data System in 2010 compiled adverse effects that were associated with exposure to CB, which included drowsiness/lethargy, hallucination/delusion, tachycardia, vomiting, agitation/irritability, chest pain, nausea, hypertension, and dizziness, which are no different than what is seen with Marinol.